Peak sales of $US250−400 million are expected by Serono for its psoriasis agent efalizumab

 

作者: &NA;,  

 

期刊: PharmacoEconomics & Outcomes News  （ADIS Available online 2004）
卷期: Volume &NA;, issue 456  

页码: 11-11

 

ISSN:1173-5503

 

年代: 2004

 

出版商: ADIS

 

数据来源: ADIS

 

 

返 回